Lupin Limited (LUPIN) — Financial Results | 12 November 2025
Lupin Limited reported record Q2 FY2026 results with total revenue of ₹7,048 crores and EBITDA of ₹2,138 crores, marking 13 consecutive quarters of YoY growth. Revenue grew 24% YoY while EBITDA surged 63% YoY, with margins expanding 750 bps to 31.3%. U.S. business grew 47% YoY (USD 315 million), India grew 3.4% YoY, and Emerging Markets grew 45% YoY. Regulatory approvals included generic Victoza and Risperdal LAI. Net cash position strengthened to ₹1,665 crores from ₹310 crores. Management raised FY26 EBITDA margin guidance and expects 24-25% margins in FY27, with planned investments including USD 250 million Coral Springs manufacturing facility.
About Lupin Limited (LUPIN)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when LUPIN files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track LUPIN — Free💡 Ask AI about this filing
📊 More LUPIN filings
- Announcement — 12 August 2026 Lupin reported record Q1 FY27 revenue of INR 8,277 crores and EBITDA of INR 2,464 crores, up 32% and...
- Announcement — 10 August 2026 Lupin Limited announced that the U.S. FDA approved its Abbreviated New Drug Application for Sodium Z...
- Announcement — 10 August 2026 Lupin Limited announced its participation in several upcoming investor conferences, including Equiru...
- Announcement — 7 August 2026 Lupin Limited announced that an audio recording of its Q1 FY27 earnings call held on August 7, 2026,...
- 🟡 Board Meeting — 4 August 2026 Lupin Limited held its Forty-Fourth Annual General Meeting on August 4, 2026 via video conferencing,...
🔥 Also filed on 12 November 2025
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when LUPIN files new disclosures
Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track LUPIN — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research